(2S)-2-[[4-(4-carbamimidoylanilino)-4-oxobutanoyl]amino]butanedioic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[4-(4-carbamimidoylanilino)-4-oxobutanoyl]amino]butanedioic acid
• 化学式: C₁₅H₁₈N₄O₆
• 分子量: 350.33
• InChiKey: FGLLQYYAFANIBM-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  183
• 氢给体数：
  6
• 氢受体数：
  7

文献信息

• ANTITHROMBOTIC COMPOUND
  申请人：BUIJSMAN Christian Rogier

  公开号：US20070293442A1

  公开（公告）日：2007-12-20

  The present invention relates compounds of the formula A oligosaccharide-spacer-GpIIb/IIIa antagonist   (A). The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases.

  本发明涉及公式A寡糖-间隔物-GpIIb/IIIa拮抗剂的化合物。本发明的化合物具有抗血栓活性，并可用于治疗或预防血栓性疾病。
• US5625093A
  申请人：——

  公开号：US5625093A

  公开（公告）日：1997-04-29
• US7576071B2
  申请人：——

  公开号：US7576071B2

  公开（公告）日：2009-08-18
• [EN] SUBSTITUTED beta -AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS<br/>[FR] DERIVES D'ACIDES AMINES beta SUBSTITUES UTILES EN QUALITE D'INHIBITEURS D'AGREGATION DE PLAQUETTES
  申请人：G.D. SEARLE & CO.

  公开号：WO1996037464A1

  公开（公告）日：1996-11-28

  (EN) Novel substituted amino acid derivatives are provided which inhibit platelet aggregation and which are useful in pharmaceutical compositions and methods of inhibiting platelet aggregation.(FR) Cette invention concerne de nouveaux dérivés d'acides aminés substitués, lesquels permettent d'inhiber l'agrégation des plaquettes et sont utiles dans des compositions pharmaceutiques. Cette invention concerne également des procédés d'inhibition de l'agrégation des plaquettes.
• [EN] ANTITHROMBOTIC COMPOUND<br/>[FR] COMPOSE ANTITHROMBOTIQUE
  申请人：SANOFI AVENTIS

  公开号：WO2005090382A1

  公开（公告）日：2005-09-29

  The present invention relates compounds of the formula (A) oligosaccharide-spacer-GpIIb/IIIa antagonist (A), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is a bond or an essentially pharmacologically inactive linking residue; the GpIIb/IIIa antagonist is a residue mimicking the RGD and/or K(QA)GD fragment of fibrinogen, typically comprising an optionally esterified carboxylate moiety and a basic moiety located within the residue at a distance of 10-20 Å from each other; or a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases.